AP2007004160A0 - Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia - Google Patents

Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia

Info

Publication number
AP2007004160A0
AP2007004160A0 AP2007004160A AP2007004160A AP2007004160A0 AP 2007004160 A0 AP2007004160 A0 AP 2007004160A0 AP 2007004160 A AP2007004160 A AP 2007004160A AP 2007004160 A AP2007004160 A AP 2007004160A AP 2007004160 A0 AP2007004160 A0 AP 2007004160A0
Authority
AP
ARIPO
Prior art keywords
pyridoazepin
schizophrenia
tetrahydro
ones
treatment
Prior art date
Application number
AP2007004160A
Other languages
English (en)
Inventor
David Favor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AP2007004160A0 publication Critical patent/AP2007004160A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2007004160A 2005-04-01 2006-03-20 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia AP2007004160A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66744705P 2005-04-01 2005-04-01
PCT/IB2006/000900 WO2006103559A1 (en) 2005-04-01 2006-03-20 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
AP2007004160A0 true AP2007004160A0 (en) 2007-10-31

Family

ID=36763625

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004160A AP2007004160A0 (en) 2005-04-01 2006-03-20 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia

Country Status (25)

Country Link
US (1) US20060234997A1 (xx)
EP (1) EP1869041A1 (xx)
JP (1) JP4109709B1 (xx)
KR (1) KR20070112228A (xx)
CN (1) CN101189237A (xx)
AP (1) AP2007004160A0 (xx)
AR (1) AR053835A1 (xx)
AU (1) AU2006228426A1 (xx)
BR (1) BRPI0607918A2 (xx)
CA (1) CA2603049A1 (xx)
CR (1) CR9407A (xx)
DO (1) DOP2006000071A (xx)
EA (1) EA200701856A1 (xx)
GT (1) GT200600130A (xx)
IL (1) IL185770A0 (xx)
MA (1) MA29989B1 (xx)
MX (1) MX2007012083A (xx)
NL (2) NL1031489C2 (xx)
NO (1) NO20075477L (xx)
PE (1) PE20061196A1 (xx)
TN (1) TNSN07366A1 (xx)
TW (1) TW200714282A (xx)
UY (1) UY29447A1 (xx)
WO (1) WO2006103559A1 (xx)
ZA (1) ZA200708033B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116265A1 (en) * 2006-03-31 2007-10-18 Pfizer Products Inc. Process for making a tetrahydro-pyridoazepin-8-one compound
US8674790B2 (en) 2009-12-28 2014-03-18 Seiko Epson Corporation Surface acoustic wave device, oscillator, module apparatus
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3402796B1 (en) 2016-01-15 2020-11-18 Pfizer Inc 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
DK3552017T3 (da) 2016-12-09 2022-05-16 Denali Therapeutics Inc Forbindelser, der er anvendelige som ripk1-inhibitorer
WO2022212538A1 (en) * 2021-03-31 2022-10-06 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
FR2699918B1 (fr) * 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
CA2603049A1 (en) 2006-10-05
KR20070112228A (ko) 2007-11-22
JP2008534574A (ja) 2008-08-28
MA29989B1 (fr) 2008-12-01
US20060234997A1 (en) 2006-10-19
IL185770A0 (en) 2008-01-06
EP1869041A1 (en) 2007-12-26
JP4109709B1 (ja) 2008-07-02
NO20075477L (no) 2007-12-13
GT200600130A (es) 2007-02-14
WO2006103559A1 (en) 2006-10-05
NL1033562A1 (nl) 2007-06-21
NL1033562C2 (nl) 2007-10-23
AR053835A1 (es) 2007-05-23
NL1031489A1 (nl) 2006-10-03
TNSN07366A1 (fr) 2008-12-31
EA200701856A1 (ru) 2008-02-28
TW200714282A (en) 2007-04-16
BRPI0607918A2 (pt) 2009-10-20
AU2006228426A1 (en) 2006-10-05
CR9407A (es) 2008-01-29
CN101189237A (zh) 2008-05-28
ZA200708033B (en) 2008-11-26
MX2007012083A (es) 2007-11-20
PE20061196A1 (es) 2006-12-16
DOP2006000071A (es) 2006-10-15
NL1031489C2 (nl) 2007-04-02
UY29447A1 (es) 2006-10-31

Similar Documents

Publication Publication Date Title
HK1221956A1 (zh) 用於治療感染的鹵代類苯酞化硼
HK1127489A1 (en) Pyridiazinone derivatives for the treatment of tumours
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
HK1131141A1 (en) Imidazolothiazole compounds for the treatment of disease
EP1965827A4 (en) TREATMENT OF CONDITIONS RELATED TO DEMYELINATION
ZA200706113B (en) Method for the treatment of copper-bearing materials
HK1164767A1 (en) Compounds and methods for the treatment of cancer
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
GB0518508D0 (en) Treatment of waste
GB0517387D0 (en) Combinations for the treatment of cancer
HK1097831A1 (en) Benzopyran compounds useful for the treatment of arrhytmia
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
IL226363A0 (en) Compounds and methods for treating cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
HU0500947D0 (en) Composition for treatment of paradontosis
WO2006081350A8 (en) Methods and compositions for the diagnosis and treatment of schizophrenia
ZA200606780B (en) Compounds for the treatment of diseases
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
GB0602857D0 (en) The treatment of sialorrhoea
GB0517386D0 (en) Combinations for the treatment of cancer
TJ20050863A (en) The way of narcotism treatment
ZA200805398B (en) Use of kcnq-openers for treating or reducing the symptons of schizophrenia
ZA200410080B (en) Composition for the treatment of humans
GB0518003D0 (en) Treatment of hepatatis c
GB0602858D0 (en) The treatment of sialorrhoea